Join
Live feed
·
PRReleasevia Quantisnow
89bio Inc. logo

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

ByQuantisnow·Wall Street's wire, on your screen.
ETNB· 89bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ETNB (89bio Inc.) and more on Quantisnow.